AKTX News & Events

Akari Therapeutics announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board.

Akari Therapeutics announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board. She currently serves as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center, and holds a joint faculty appointment at University of Connecticut School of Medicine, where she leads a multidisciplinary research program focused on elucidating the mechanisms by which alternative RNA splicing, a fundamental process in gene expression regulation, becomes misregulated in cancer and drives tumor initiation, progression, metastasis, and therapeutic resistance.

Akari Therapeutics announced the filing of a new U.S. provisional patent application covering its second pipeline candidate, AKTX-102, an ADC directed against CEACAM5, a well-validated but historically difficult-to-drug oncology target. Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, commented, "This patent filing marks another important step in expanding Akari's differentiated ADC platform and rapidly growing pipeline. AKTX-102 builds on our deep and unique insights into CEACAM5 tumor biology and we believe demonstrates the versatility of our PH1 payload and our antibody expertise to unlock previously intractable targets. We believe PH1 can serve as the foundation for a pipeline of novel ADCs, and this program highlights our innovation on novel payloads for ADCs as well as with tumor antigen biology and antibody engineering to build best-in-class ADCs."